SEC Form 4 · accession 0001225208-17-005738
JOHNSON & JOHNSON · JNJ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joaquin Duato
Officer — Exec VP, WW Chair, Pharma
Period of report
Mar 3, 2017
Accepted (ET)
Mar 7, 2017 · 4:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000200406
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 3, 2017 | M | 29,158 | $58.33 | A | 97,694 | D | |
| Common Stock | Mar 3, 2017 | M | 20,842 | $61.75 | A | 118,536 | D | |
| Common StockF1 | Mar 3, 2017 | S | 50,000 | $123.6228 | D | 68,536 | D | |
| Common StockF2 | holding | — | — | — | 570 | I | By 401k |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Options (Right to Buy) | $58.33 | Mar 3, 2017 | M | 29,158 | D | Feb 10, 2012 | Feb 8, 2019 | Common Stock | 29,158 | 5,130 | D |
| Employee Stock Options (Right to Buy) | $61.75 | Mar 3, 2017 | M | 20,842 | D | Feb 12, 2011 | Feb 10, 2018 | Common Stock | 20,842 | 0 | D |
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $123.35 to $123.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (2/28/2017).